Boston Scientific Corp (BSX) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Boston Scientific Corp (BSX)

43.56

-0.21 (0.48%)

as of Jul 21, 2026, 2:50:53 pm Market Open.

101 watching

Investor Insights

Jul 21, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

Boston Scientific Corp (BSX) is currently experiencing significant challenges, with analysts noting a series of lower highs and lows since 2025, leading to a breach of key support levels such as the $50 mark. While the company is recognized as a leader in the medical device sector—especially in non-invasive heart instrumentation—its organic growth has diminished, with recent guidance cuts on critical products like the Watchman device impacting market sentiment. Investor confidence is wavering due to rising competition from peers like MDT, ABT, and JNJ, as well as deteriorating technical indicators, such as being below the 200-day moving average. Despite these challenges, some analysts hint at potential long-term growth due to evolving demographic factors and a shift towards less invasive medical solutions, although immediate prospects appear uncertain.

Consensus

Negative

Valuation

Overvalued

Similar

DHR

DON'T BUY

Had an earnings disappointment. FMV trend is sharply down. When factoring in analysts forecasts, the FMV is about $12.30.

BUY ON WEAKNESS

Will have to go to $20.50 before it has a bounce. Has a model price of $31.95 which is a 37/38% differential.

BUY

In a lawsuit with Johnson and Johnson (JNJ-N), so a lot depends on who wins the case. Their product works better than JNJ and he continues to like it.

BUY

Things look good for them. Won a patent case against Johnson & Johnson (JNJ-N).

WEAK BUY

It's close to a buy. Model price is $32.09 which is a 5% differential.

TOP PICK

"We really like Boston [Scientific]" Thinks they have a better product then the competitor. Had a series of recalls, but have been able to gain back the marketshare. But the stock didn't recover as well. So is now undervalued.

DON'T BUY

Long term chart shows that it made a base, had a fantastic rise to $45 in 2002/2003, very little top formation and now we are in a downtrend. Stock has now fallen below its 200 day moving average.

BUY

A good company. Their coated stents is a terrific product. Up against Johnson & Johnson in the stent business, but they are holding their own. A good buy at this price.

WEAK BUY

Stock has dropped because of the recall of their stent. Price is reasonably attractive.

TOP PICK

A company that focuses on earnings. A tremendous new product that should give a nice boost to their income.

DON'T BUY

Its drug coated stent is driving the price up, but other competitors are lurking on the horizon. Not cheap.

TOP PICK

Likes this sector. Strong and persistant growth. Revenue and earnings growth has been very persistant. Good products. Buy on pull backs.

Showing 61 to 72 of 72 entries

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

David Driscoll

Liberty International Investment Management Inc

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Capital Area Planning Group

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Boston Scientific Corp (BSX)